You are here

RedHill Biopharma Reports 2017 Second Quarter Financial Results

RedHill maintains a debt-free balance sheet with $51 million cash1 at the end of the second quarter of 2017  Select recent milestones include: Initial net revenues of approximately $0.5 million between June 12-30 following commencement of promotional activities in the U.S. by RedHill’s GI-focused sales force with two GI specialty products, Donnatal® and EnteraGam® Positive top-line […]